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family of bioactive peptides. Galanin exerts its biological activity through three G-protein coupled receptor
subtypes, GAL1–3R. Throughout the last 20 years, data has accumulated that galanin can have a neuroprotective
effect presumably mediated through the activation of GAL1R and GAL2R. In order to test the pharmaceutical
potential of galanin receptor subtype selective ligands to inhibit excitotoxic cell death, the GAL1R selective ligand
M617 and the GAL2R selective ligand M1145 were compared to the novel GAL1/2R ligand M1154, in their ability
to reduce the excitotoxic effects of intracerebroventricular injected kainate acid in rats.
The peptide ligands were evaluated in vitro for their binding preference in a competitive 125I-galanin receptor
subtype binding assay, and G-protein signaling was evaluated using both classical signaling and a label-free
real-time technique. Even though there was no signiﬁcant difference in the time course or severity of the
kainic acid induced epileptic behavior in vivo, administration of either M617 or M1154 before kainic acid
administration signiﬁcantly attenuated the neuronal cell death in the hippocampus. Our results indicate the
potential therapeutic value of agonists selective for GAL1R in the prevention of neuronal cell death.
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M11541. Introduction
Excitotoxicity is involved in a variety of acute and chronic neuro-
degenerative conditions in the central nervous system (CNS) such as
hypoxia–ischemia, status epilepticus, Alzheimer's disease, Parkinsons
disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis
(MS). Neuronal damage by glutamate excitotoxicity was identiﬁed as
early as 1969 (Olney, 1969) and has been extensively studied since
then. Despite more than 50 years of research, there are currently no
pharmacological interventions in the clinical settings of acute neuro-
degenerative conditions.
One of themostwell documented excitotoxins is kainic acid (KA), an
analog of glutamic acid, which induces the pathological changess; DMEM, Dulbecco's modiﬁed
in receptor subtype 1; GAL2R,
subtype 3; HEK cells, human
ic acid.
Webling).
. This is an open access article underpartially mimicking neurodegeneration. Thus, KA-induced murine
neurodegeneration has been used as a model for exploring relevant
pharmacological treatment of excitotoxicity in neurodegenerative dis-
orders. Furthermore, central administration of KA has been shown to
produce convulsions through activation of the excitatory amino acid re-
ceptors. Therefore, administration of KA has also been used as a model
for the study of epilepsy (Ben-Ari and Cossart, 2000). Centrally admin-
istered KA induces secondary damage in a number of structures and
areas associated with the epileptic seizure, i.e. the cell damage is not
caused by a direct KA-induced excitotoxic mechanism (Jarrard, 2002).
It can therefore bedifﬁcult to dissociate direct and indirect neuroprotec-
tive effects in paradigms where seizures are induced, since an indirect
neuroprotection through anticonvulsant properties of any pharma-
ceutical might be interpreted as a direct neuroprotective action of the
drug (Mazarati, 2004). Subsequently, in the present study, KA was
administered intracerebroventricular (i.c.v.) in a dose that was earlier
optimized to ensure neuronal cell death with a direct excitotoxicmech-
anism (Reiss et al., 2009), thus allowing us to study the neuroprotective
components of the ligands used.
There are numerous compounds that have been proposed to have
either or both neuroprotective and anticonvulsant activities. One ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Amino acid sequences of peptides used or discussed in this study.
Name Sequence Reference
Galanin
(1–29), rat
GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-amide Vrontakis et al.
(1987)
Galanin
(1–16)
GWTLNSAGYLLGPHAI-amide Land et al.
(1991)
Galanin
(2–11)
WTLNSAGYLL-amide Liu et al.
(2001)
M617 GWTLNSAGYLLGPQPGFSPFR-amide Lundström et al.
(2005)
M1145 RGRGNWTLNSAGYLLGPVLPPPALALA-amide Runesson et al.
(2009)
M1154 GWTLNSAGYLLPQPGFSPFA-amide
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humans) bioactive peptide distributed in brain, spinal cord and gut,
which has been ascribed involvement in a diversity of physiological ac-
tions (Lang et al., 2007) such as food intake (Saar et al., 2011), mood
(Kuteeva et al., 2008), nociception (Jimenez-Andrade et al., 2006), mod-
ulating the effects of drug abuse (Jackson et al., 2011) and recently in reg-
ulation of hair growth (Holub et al., 2012). The expression of galanin is
highly plastic and markedly up-regulated in many areas under certain
physiological conditions. Galanin exerts its effects via three members
(GAL1–3R) of theG-protein-coupled receptor (GPCR) superfamily. The re-
ceptors have distinct distribution patterns, as well as different signaling
pathways (Lang et al., 2015). GAL1R and GAL3R has been reported to pre-
dominantly signal through Gi/o, leading to reduced cAMP-levels, whereas
GAL2R mainly signal through Gq/11, leading to inositol phosphate accu-
mulation and an increase in intracellular [Ca2+] (Branchek et al., 2000).
It has been shown that galanin plays a developmental survival role
and functions as a trophic factor to adult neurons (Abbosh et al.,
2011). By utilizing several transgenicmouse lines and theGAL2/3R selec-
tive ligand galanin (2–11), Wynick and colleagues have previously
demonstrated that GAL2R mediates this effect (Hobson et al., 2008).
Several lines of evidence reveal that galanin functions as an endoge-
nous neuroprotective factor for hippocampal neurons. A recombinant
adeno-associated viral (AAV) system that overexpresses galanin together
with the ﬁbronectin secretory signal sequence attenuates the neuronal
death of centrally administeredKA (Habermanet al., 2003). Furthermore,
transgenic galanin knock-out mice display a greater cell death than
wildtype littermates when KA is administered i.p., and in concordance
with this a reduction of cell death is seen in galanin overexpressing
(OE) mice (Elliott-Hunt et al., 2004). In vitro studies in hippocampal cul-
tures from these transgenic mice have conﬁrmed that endogenous
galanin diminishes excitotoxicity and apoptosis (Elliott-Hunt et al.,
2004). The authors proposed that this neuroprotection is mediated pri-
marily through the regulation of hippocampal excitability. A recent
study showed that administration of M15, a non-selective galanin recep-
tor antagonist signiﬁcantly increases cell death in several hippocampal
areas after systemic administration of KA (Schauwecker, 2010).
There are conﬂicting data regarding which receptor subtype medi-
ates this neuroprotective role of galanin. Studies utilizing organotypic
and dispersed primary hippocampal cultures have shown the impor-
tance of GAL2R in galanin-mediated neuroprotection,when cell cultures
are exposed to staurosporine (Elliott-Hunt et al., 2004), glutamate
(Pirondi et al., 2005) and amyloid-β (Ding et al., 2006). In contrast,
Elyse Schauwecker and colleagues have shown in a series of publica-
tions that there is a correlation between the expression level of GAL1R
and neuronal cell death after excitotoxic assaults by systemic adminis-
tration of KA (Kong et al., 2008; Schauwecker, 2010). Furthermore, it
has been reported that GAL1R knock-out mice have an enhanced sus-
ceptibility to excitotoxin-induced neuronal injury (Mazarati et al.,
2004; Mazarati, 2004). In order to delineate the contribution of the dif-
ferent galanin receptors, galanin receptor subtype selective ligands are
needed, however to date only a few galanin receptor subtype selective
ligands are available (Lang et al., 2015; Webling et al., 2012).
Recently, label-free real-time technologies have emerged as a pow-
erful tool to study GPCR signaling. These techniques have numerous ad-
vantages including that neither the ligand nor the receptor require
labeling; simplifying assay design and minimizing artifacts or liabilities
created by the labeling process (Minor, 2008; Nayler et al., 2010; Scott
and Peters, 2010). Cellular impedance based technology detects small
changes in the contact area between cells and electrodes. These changes
can be due to alterations in cell numbers and/or cell morphology, which
is both affected by GPCR signaling (Scott and Peters, 2010). With this
single detection system the responses from several GPCRs, known to
couple to different signaling pathways can be quantiﬁed. This gives a
huge advantage particularly when screening for subtype selective li-
gands of galanin receptors, since the galanin receptor subtypes have
been shown to signal through different G-proteins.In this study, we present a novel peptide with GAL1/2R selective
binding, namelyM1154 (for sequence see Table 1). Furthermore, we in-
troduce a single protocol for screening new ligands for subtype selective
receptor signaling for all three galanin receptor subtypes,which is likely
to promote the research effort to develop galanin receptor subtype spe-
ciﬁc ligands. M1154 together with previously published galanin recep-
tor subtype selective ligands M617 and M1145 were evaluated in an
excitotoxic assay using i.c.v. administrated KA in rats.
2. Materials and methods
2.1. Peptide sequence design
The N-terminal part of galanin, residue 1–14, is highly conserved
among species and is vital for receptor interaction and biological activ-
ity. Exemplifying the importance of the N-terminal portion of galanin
for receptor binding, galanin(1–16), despite lacking half the galanin
sequence, retains high afﬁnity binding (Table 2). All three receptors dis-
play high afﬁnity for galanin but are distinguishable by the fact that
GAL1R does not tolerate N-terminal deletions of the galanin peptide in
comparison to the other two receptors. This difference has successfully
been used in the design of several peptides, including the M871
(Sollenberg et al., 2006, 2010) and the M1145 peptide (Runesson
et al., 2009), which both bind less to GAL1R compared to GAL2R. An im-
portant advance in the ﬁeldwas the publication of the galanin fragment,
galanin (2–11), as a non-GAL1R ligand (Liu et al., 2001; Lu et al., 2005).
Two GAL1R preferential ligands have also been developed, the M617
and the Gal-B2, with a modest, 25-fold and 15-fold selectivity for
GAL1R compared to GAL2R respectively (Bulaj et al., 2008; Lundström
et al., 2005). The GAL3R interaction for M617 has also been charac-
terized, showing a 200-fold difference when compared with GAL1R
(Sollenberg et al., 2010).
Thenovel peptideM1154 (for sequence see Table 1)was designed to
minimize afﬁnity to GAL3R, as a mixed GAL1/2R ligand has been impli-
cated as a putative therapeutic in several cases (Mitsukawa et al.,
2008). For the design of M1154, particular interest was turned to the
M617 peptide and its high afﬁnity for GAL1R. Deletion of Gly12 in several
galanin analogous severely affects the interactionwith GAL3R relative to
GAL1R and GAL2R (Runesson et al., unpublished data), possibly due to
the narrow binding pocket in GAL3R (Runesson et al., 2010) which
does not tolerate the relative movement of the Pro13 induced kink in
these galanin analogous. Furthermore, we have shown earlier that the
Ala21Arg mutation in M617 reduces the GAL3R afﬁnity six-fold
(Sollenberg et al., 2010). M1154 combines these two modiﬁcations
known to reduce GAL3R afﬁnity relative to the other two galanin recep-
tor subtypes, creating a GAL3R non-interacting galanin receptor ligand.
2.2. Cell culture
Bowes human melanoma cells (American type Culture Collection
CRL-9607) expressing human GAL1R were cultured in Eagle's minimal
Table 2
Experimental Ki determined by displacement studies with Porcine-[125I]-Galanin on Bowes Melanoma Cells expressing human GAL1R, CHO cells stably transfected with human GAL2R or
Flp-In T-REX 293 cells with tetracycline induced expression of human GAL3R.
Name
Ki (nM)
Ki GAL1R/Ki GAL2R Ki GAL3R/Ki GAL2R
GAL1R GAL2R GAL3R
Galanin 1.75 ± 1.7a 2.98 ± 1.4a 4.49 ± 0.8a 0.6 1.5
Galanin(1–16) 0.78 ± 0.26 2.44 ± 0.57 8.98 ± 3.8 0.3 3.7
M617 0.23 ± 0.1b 5.71 ± 1.3b 49 ± 9.4c 25 8.6
M1145 587 ± 250a 6.55 ± 2.7a 497 ± 150a 90 76
M1154 11.7 ± 7.2 14.4 ± 4.1 N15,000 0.8 N1000
a Runesson et al. (2009).
b Lundström et al. (2005).
c Sollenberg et al. (2010).
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vine serum (FBS), 1% sodium pyruvate, 1% non-essential amino acids,
100 U ml−1 penicillin and 100 μg ml−1 streptomycin. Chinese Hamster
Ovary (CHO) K1 cells stably expressing human GAL2R (a kind gift from
Kathryn A. Jones and Tiina P. Iismaa, Sydney, Australia)were cultured in
Dulbecco's modiﬁed essential medium (DMEM) F-12 with Glutamax
supplemented with 10% FBS, 2 mML-glutamine, 100 U ml−1 penicillin
and 100 μg ml−1 streptomycin. Human embryonic kidney (HEK) 293
cells stably expressing rat GAL2R (a kind gift from Xiaoying Lu and
Tamas Bartfai, La Jolla, USA) were cultured in DMEM supplemented
with 10% FBS, 100 U ml−1 penicillin and 100 μg ml−1 streptomycin
(Lu et al., 2010). SH-SY5Y cells with inducible expression of GAL1R or
GAL2R (Berger et al., 2004) were grown in minimum essential media
supplemented with 10% FBS, 1% sodium puruvate, 1% non-essential
amino acids and 100 U ml−1 penicillin and 100 μg ml−1 streptomycin.
Flp-In T-REx 293 GAL3R cell line (a kind gift from F. Hoffman-La Roche
Ltd., Basel, Switzerland) (Runesson et al., 2010) were cultured in
DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U ml−1
penicillin, 100 μg ml−1 streptomycin, 15 μg/ml blasticidin S and
150 μg/ml Hygromycin B (Runesson et al., 2009). Cell cultures were all
grown at 37 °C in a 5% CO2 incubator.
2.3. Peptide synthesis
Peptides were synthesized in a stepwise manner using small scale
(0.1 mmol) 9-ﬂuorenylmethyloxycarbonyl (Fmoc) solid-phase peptide
synthesis strategy on p-methylbenzylhydrylamine (MBHA) resin on an
automated Syromultiple peptide synthesizer (MultiSynTechGmbH,Wit-
ten, Germany). Fmoc-L-amino acids (Iris Biotech GmbH, Marktredwitz,
Germany) were coupled as hydroxybenzotriazole (HOBt) esters. The
peptides were ﬁnally cleaved from the resin using 95% triﬂuoroacetic
acid (TFA), 2.5% triisopropylsilane and 2.5% H2O solution for 3 h. All pep-
tides were puriﬁed by reverse-phase high-performance liquid chroma-
tography (RP-HPLC) on a Discovery® C-18 Supelco® column (Sigma-
Aldrich, Stockholm, Sweden) using a gradient of acetonitrile/water con-
taining 0.1% TFA. The identity of the puriﬁed products was veriﬁed by
Perkin Elmer prOTOF™ 2000 matrix-assisted laser desorption ionization
time-of-ﬂight mass-spectrometer (Perkin Elmer, Upplands Väsby,
Sweden). The mass-spectra were acquired in positive ion reﬂector
mode using α-cyano-4-hydroxycinnamic acid as a matrix (Sigma-Al-
drich, Stockholm, Sweden) (10 mg/ml, 7:3 acetonitrile:water, 0.1% TFA).
2.4. Galanin receptor binding studies
Cells for 125I-galanin-receptor displacement studies were seeded in
150 mm cell culture dishes and cultured 2–4 days until conﬂuent. The
GAL3R inducible cell line was treated with tetracycline (1 μg/mL) 24 h
prior to cell harvesting for inducing expression of GAL3R. The dishes
werewashed thrice and cells scraped off into phosphate-buffered saline
(PBS) and centrifuged twice at 4 °C, 3000 ×g for 5 min. The pellet was
resuspended in assay buffer (20 mM HEPES, 5 mMMgCl2, pH 7.4) sup-
plemented with EDTA (5 mM) and incubated on ice for 45 min beforecentrifugation at 4 °C, 8500 ×g for 15 min. After washing the pellet in
assay buffer and repeated centrifugation the obtained pellet was resus-
pended in assay buffer supplemented with 1% protease inhibitor cock-
tail (Sigma-Aldrich, St. Louis, MO, USA) and stored at −80 °C until
use. The protein concentration was determined according to Bradford
(BioRad, Stockholm, Sweden). Displacement studies on cell membranes
were performed in a ﬁnal volume of 200 μl, containing 0.1–0.12 nM
porcine-[125I]-galanin (2200 Ci/mmol, Perkin–Elmer Life Science,
Boston, MA, USA), 30 μg cell membrane, and various concentrations of
peptide (10−5–10−11 M). Peptides were diluted in assay buffer supple-
mented with 0.3% BSA using silanized (dichlorodimethylsilane, Sigma-
Aldrich, St. Louis, MO, USA) tubes, 96-well plates and pipette tips.
Samples were incubated at 37 °C for 30 min while shaking. After that
the samples were transferred and ﬁltered through a MultiScreen-FB
ﬁlter plate (Millipore, Billerica, MA, USA) pre-soaked in 0.3% polyethyl-
enimine solution (Sigma-Aldrich, St. Louis, MO, USA) and removed
using vacuum. The ﬁlters were washed thrice with HM-buffer and the
retained radioactivity was determined in a β-counter (Tri-Carb Liquid
Sqintillation Analyzer, model 2500 TR, Packard Instrument Company,
Meriden, CT, USA) using OptiPhase Supermix Cocktail (Perkin–Elmer
Life Science, Boston, MA, USA) as scintillation ﬂuid. IC50 values for the
peptides were calculated using Prism 5.0 (GraphPad Software Inc., San
Diego, CA, USA) and converted into Ki values using the equation of
Cheng–Prusoff (Cheng and Prusoff, 1973).
2.5. Galanin receptor signaling studies — cAMP measurements
SH-SY5Y cells stably expressing GAL2R were seeded in a 48 well
plate and grown to conﬂuency. Media was then changed to DMEM con-
taining [3H]adenine (3 uCi/ml) purchased fromPerkin Elmer (Waltham,
MA, USA) for 2 h. The cells werewashed twicewithHank's balanced salt
solution (HBSS) before treated with 20 μM forskolin and/or M1154 for
30 min in the presence of 1 mM 3-isobutylmethylxanthine (IMBX),
BAY 60-7550 (1 μM) and rolipram (10 μM) or with HBSS alone. The
buffer were then removed and cells lysed with 5% (w/v) trichloroacetic
acid followed by 250 μL trichloroacetic acid supplemented with cAMP
(0.1 mM) and ATP (0.1 mM) for 20 min at 4 °C. The lysates were stored
at−80 °C until applied to Dowex 50 W-X4 columns (200–400 mesh)
and washed with water and subsequently placed over alumina col-
umns. The alumina columns were washed with water before placed
over scintillation vials and eluted with 6 mL imidazole (0.1 M). To
each vial 10 mL scintillation liquid (Ultima Gold XR) were added and
the samples were analyzed in a liquid scintillation counter (Tri-Carb
model 1600 TR; Packard Instrument Company).
2.6. Galanin receptor signaling studies — label-free real time technology
The xCELLigence system (Roche Diagnostics, Sweden) is based on
the ACEA RT-CES cell sensor electrodes, which allow monitoring and
analysis of the kinetic aspects of cellular behavior. The technology is de-
scribed in detailed elsewhere (Peters and Scott, 2009; Yu et al., 2006),
(Scott and Peters, 2010; Solly et al., 2004). Brieﬂy, this assay is based
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phology, regardless of which G-protein signaling cascade used. The
change in cell morphology inﬂuences the contact area between cells
and the electrodes on which the cells are grown and this small change
is measured in real time as impedance. Experiments were performed
using the EVIEW-Plates™ from ACEA (San Diego, CA, USA). One day be-
fore the experiment, 100 μl of medium was added to each well and
background recorded. Following background measurement, 100 μl of
media containing the cell suspension was seeded on the EVIEW-
Plate™, incubated at room temperature for 30 min and then placed on
the device station, and hosted in an incubator at 37 °C with 5% CO2.
The cells were allowed to equilibrate for 24 h (48 h for the Flp-In T-
REX 293 cell line where 1 μg/ml tetracycline was added 24 h prior to li-
gand addition to induce GAL3R expression) and impedance were con-
stantly monitored every minute throughout the whole experiment. To
evaluate the effect of cell density on impedance responses and to iden-
tify a better signal-to-noise ratio, we tested cell densities ranging from
5000 to 40,000 cells/well. Optimal density was 40,000 cells/well for
Bowes human melanoma cells stably expressing GAL1R, 30,000 cells/
well for HEK 293 cells expressingGAL2R and 20,000 cells/well for the in-
ducible Flp-in T-REX 293 GAL3R cells. Prior to the experiment, media
were replaced by 180 μl low-FBS (1%) containing cell culture media, ac-
cording to the manufactures instruction, and incubated for 1 h. Then,
20 μl of the compounds diluted in PBS, at 10× the desired concentration,
were gently added. In experiments aimed at evaluating antagonism,
both compound and galanin were added simultaneously. Data were an-
alyzed using the integrated software package expressing changes in cell
electrode impedance as changes in cell index, CI (Yu et al., 2006) and
normalized to the cell index at the time of ligand addition. Concentra-
tion effect curves were generated by calculation of the area under
curve (AUC) between 0 and 3600 s and plotted against ligand concen-
tration. The subsequently calculation of EC50 values was determined
by non-linear regression using Prism 5.0 (GraphPad Software Inc., San
Diego, CA, USA).
2.7. Behavioral experiments and cell counts in the hippocampus
Adult, male Sprague–Dawley rats (total number of 41, weighing
250–300 g) were obtained from Harlan Inc. (Indianapolis, IN, USA)
and housed individually throughout the experiment in 42 L × 22 W ×
20 H cm polycarbonate cages. Rats were maintained in a temperature
and humidity-controlled environment on a 12-h light/dark schedule.
Food and water were available ad libitum. Rats were allowed a one
week adaption to the animal facility prior to cannulation surgeries and
were randomly assigned to one of six groups (www.randomizer.org):
M1145 (10 μg; 20 μg; n = 6 respectively n = 8); M1154 (20 μg, n =
9); M617 (20 μg, n = 7); Saline Control (n = 8); Naïve Control (n =
3). All procedures were conducted in accordance with NIH Guide for
Care and Use of Laboratory Animals and were approved by the Univer-
sity of Georgia Animal Care and Use Committee. Rats were anesthetized
with a 1–3% isoﬂorane/oxygen mixture delivered through a vaporizer
and nose cone and mounted in a stereotactic frame. A longitudinal inci-
sion was made along the scalp and overlaying connective tissue and
periosteum was scraped away from the scalp. Cannulae (1 cm) were
surgically implanted into the right lateral ventricle at the following co-
ordinates (from Bregma): posterior 1.0 mm, lateral 1.5mm, and ventral
3 mm according to the rat atlas of Paxinos & Watson (Paxinos and
Watson, 1986). Cannulae were secured to the skull using 3 stainless
steel screws and epoxy. All rats received 1 mg/kg meloxicam post-
surgery. Cannulae placement was veriﬁed at the end of all procedures
by injecting 2 mg/ml of fast green dye following euthanasia and verify-
ing its presence in the ventricles. One week following surgeries, rats
were injected with one of ﬁve compounds plus 0.2 μg of kainic acid.
Doses of compounds were as follows: low dose M1145 10 μg, high
dose M1145 20 μg, M1154 — 20 μg, M617 — 20 μg, and Saline — 20 μg.
All drugs were dissolved in deionized water and injected in a volumeof 5 μl. Naïve animals did not undergo cannulation surgery or receive
any drugs. Seizure behavior was scored live by a rater blind to group as-
signment for 30 min post microinjections and video recorded for addi-
tional ratings. The rating scale was adapted from the Racine scale
(Racine, 1972; Reiss et al., 2009) and averages of seizure rating scores
were calculated for analysis. Animals were perfused transcardially
with PBS followed by a 4% formalin solution 48 h post-i.c.v. injections
and seizure rating. Brains were extracted, ﬁxed in 4% formalin solution,
and kept frozen at−20 °C until sectioned. Sections from both the dorsal
and ventral hippocampus (20 μm) were thaw mounted on slides. One
slide per region, dorsal and ventral hippocampus, was nissl-stained
and cells of the CA3 region were counted under a microscope and re-
corded. A two-way contingency table analysis of high and low seizure
scores was conducted to assess effect of treatment on seizure ratings.
A Kruskal–Wallis test was conducted to evaluate differences among
the treatment conditions; pairwise comparisons were conducted to
evaluate differences between treatment groups and saline group.
These statistical analyses were conducted using PASW Statistics Win-
dows version 18.0 (IBM Corporation, Armonk, NY, USA).
3. Results
3.1. Galanin receptor binding studies
125I-galanin-receptor displacement experiments with galanin,
galanin (1–16) and M1154 were performed on cell membranes from
human Bowes melanoma cells endogenously expressing GAL1R, CHO
K1 cells stably expressing GAL2R and Flp-In T-REX 293 cells with induc-
ible expression of GAL3R. Displacement of 125I-galanin by M1154 at
GAL1R showed a relatively high afﬁnity with a Ki of 11.7 ± 7.2 nM,
whereas galanin (1–16) had a Ki of 0.78 ± 0.26 nM in the same exper-
iments.When tested onGAL2R,M1154had a Ki of 14.4±4.1 nMwhere-
as galanin (1–16) had a Ki of 2.44 ± 0.57 nM on the same receptor and
cell line. When tested on GAL3R M1154 showed no binding up to 10
000 nM, whereas galanin (1–16) had a Ki of 8.98 ± 3.8 nM see
(Table 2; Fig. 1b). These results suggest that M1154 is selective for
GAL1/2R and the difference towards GAL3R is greater than 1000 times
(Table 2; Fig. 1a).
3.2. Galanin receptor signaling studies using cAMP measurements
GAL1R and GAL2R expressing SH-SY5Y cells were treated with
M1154 at different concentrations (13 nM–10 μM) together with
20 μM forskolin. The GAL1/2R-selective agonist M1154 decreases
forskolin stimulated cyclic adenosine-monophosphate production
signiﬁcantly in a dose-dependent manner in GAL1R expressing cells
with an EC50 of 159.6 nM (See Table 3, Fig 2A). In contrast, in SH-
SY5Y cells expressing GAL2R M1154 increases the cAMP production
dose-dependently with an EC50 of 1.53 μM (See Table 3, Fig 2B).
3.3. Galanin receptor signaling studies using a real-time label-free
technique based on impedance
To assess if galanin receptor stimulation could be detected by
using an impedance based technology, xCELLigence, cells were chal-
lenged with the full-length galanin. Compound addition induced a fast
concentration-dependent response in normalized cell index (NCI)
with different concentration dependent proﬁles for each receptor sub-
type (Fig 3A-D). Two different GAL2R cell lines were characterized,
CHO cells expressing human GAL2R and HEK cells expressing rat
GAL2R. These cell lines displayed similar proﬁles for galanin (Fig 3B-
C), although the signal to noise ratio was signiﬁcantly higher in the
HEK cells and this cell line was therefore continuously used. Because
the instrumentmonitors the impedance changes elicited by receptor ac-
tivation in real time, it is possible to generate concentration-activity
curves in a variety of ways, dependent on the time point or period of
Fig. 1. Galanin receptor binding studies. Displacement of porcine-[125I]-galanin from membranes by peptide M1154 (A) and the galanin fragment, galanin(1–16) (B). Membranes were
from human Bowes melanoma cells expressing GAL1R (open circle), CHO cells expressing GAL2R (closed square) and Flp-In T-REx 293 cells expressing GAL3R (closed triangle). The
data is from three representative experiments performed in duplicates, presented as mean ± SEM. Calculated Ki values are summarized in Table 2.
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robust protocol that could be used independent of the type of activated
G-protein and eliminate the need for a clear peak maximum, since that
is not often seen in the literature (Schroeder et al., 2010; Scott and
Peters, 2010). Qualiﬁcation of normalized cell index, NCI, signals for
concentration effect curves and the subsequently calculation of EC50
was therefore performed by calculation of the AUC between 0 and
3600 s. Galanin showed similar EC50 values to GAL1R and GAL2R,
1.1 ± 0.11 nM and 8.26 ± 1.9 nM, respectively (Table 3, Fig 3), while
the EC50 towards GAL3R was 412 ± 38 nM. In the present study,
M617 displays EC50-values that are considerable lower at GAL1R and
GAL2R, 11.4 ± 0.67 nM and 24.6 ± 3.8 nM, respectively (Table 3, Fig
3), although the relative three time preference for GAL1R over GAL2R
was observed in both studies. In the present setup, M617 displays an
EC50-value of 2840 ± 1090 nM for GAL3R which results in a signaling
proﬁle for the galanin receptor subtypes more in concordance with
the binding proﬁle (Table 2 and Table 3). We have previously shown
the agonistic properties at GAL2R of M1145 in an IP accumulation
assay, with an EC50 value of 38 nM (Runesson et al., 2009). In this
study, a slightly lower EC50-value of 16 ± 4.7 nM was obtained with
the xCELLigence system. Here, we also characterize for the ﬁrst time
the ability of M1145 to activate GAL1R and GAL3R. M1145 acts as an ag-
onist at all receptor subtypes, although the potency varies signiﬁcantly,
with a more than 70 times difference in the calculated EC50-values
(Table 4, Fig 4). The novel peptide,M1154, displayed a slightly lower po-
tency than galanin at GAL1R and GAL2R with an EC50-value of 124 ±
47 nM and 26 ± 1.1 nM, respectively. M1154 had no effect at any con-
centration tested on GAL3R (Table 4, Fig 4). To address the efﬁcacy of
M1154, the maximal response induced by M1154 were compared to
the maximal response (Emax normalized to 100 percentage) inducedTable 3
Obtained EC50-values for rat galanin and galanin receptor ligands in signaling studies uti-
lizing traditional end-point assays, cAMP (GAL1R), cAMP or IP-production (GAL2R) and
GTPγS (GAL3R). Cells used were Bowes Melanoma Cells expressing GAL1R, CHO, SH-
SY5Y or HEK cells stably transfected with GAL2R or Flp-In T-REX 293 cells expressing
GAL3R.
Name
EC50 (nM)
GAL1R GAL2R GAL3R
RT-CES Galanin(1–29) 1.1 8.3 412
Galanin(1–29) 31.6a 173a 530b
M1145 n.t 38b n.t
M617 104a 304a 121c
M1154 159 1530 n.t
n. t not tested
a Lundström et al. (2005).
b Runesson et al. (2009).
c Sollenberg et al. (2010).
Fig. 2. Galanin receptor signaling studies utilizing cAMP measurements of M1154 on SH-
SY5Y cells expressing GAL1R (A) andGAL2R (B). Data presented aremean values of at least
triplicates ± SEM. * p-value ≤0.05, **p-value ≤0.01 and *** p-value ≤0.001.
Fig. 3. Galanin receptor signaling studies utilizing the Impedance based (RT-CES) system. Concentration dependent proﬁles of galanin or the galanin fragment, galanin (1–16), in
(A) Bowesmelanoma cells expressing human GAL1R, (B) CHO K1 cells expressing human GAL2R, (C) HEK cells expressing rat GAL2R, (D) Flp-In T-REX 293 cells with tetracycline induced
expression of human GAL3R.
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galanin (data not shown). Application ofM1154 (10 nM) induced a shift
to the left of the concentration activity curve of galaninwith a consistent
modiﬁcation of the EC50 (EC50 = 21 nM), conﬁrming a M1154-
mediated agonistic effect (Fig 5). Application of galanin (1 or 10 nM) in-
duced a similar shift to the left of the concentration activity curve of
M1154 (EC50 = 10–90 nM) (Fig 3B), conﬁrming again the both galanin
and M1154-mediated an agonist effect.
3.4. Behavioral experiments and hippocampal cell counts
KA (0.2 μg) administered i.c.v. induced seizures-typical behaviors to
a similar extent as reported in previous studies (Reiss et al., 2009). A
Pearson chi square test revealed no signiﬁcant changes in the seizure
rating scores for any of the administered galanin receptor ligands,
χ2(4,N=38)= 1.839, p=0.765 (Fig 6). Administration of KA resulted
in a dramatic cell loss in the CA3 region (Fig 7) for both dorsal and
ventral hippocampus.When the cell number was quantiﬁed, a trend to-
wards a reduction of cell deathwas seen for all co-administrated galanin
receptor ligands (Fig 7). The results from an independent samples
Kruskal–Wallis tests for cell count differences among treatments indi-
cated signiﬁcance after KAadministration for both thedorsal hippocam-
pus, χ2(5, N= 41) = 18.248, p= 0.003; and the ventral hippocampus,
χ2(5,N=38)=15.702, p=0.008. Follow-up pairwise comparisons in-
dicated that cell counts in the dorsal hippocampus were signiﬁcantly
different from the vehicle treatment for two groups, M1154 + KA
(p= 0.038) and M617 + KA (p= 0.001). Additionally, pairwise com-
parisons indicated that cell counts in the ventral hippocampus wereTable 4
Potency of galanin receptor ligands in the impedance (RT-CES) system. Cells used where Bowe
Flp-In T-REX 293 cells with tetracycline induced expression of human GAL3R.
Name
EC50 (nM)
GAL1R GAL2R GAL3R
Galanin(1–29) 1.1 ± 0.11 8.26 ± 1.9 412
M617 11.4 ± 0.67 24.6 ± 3.8 2840
M1145 1260 ± 119 16 ± 4.7 2670
M1154 124 ± 47 26 ± 1.1 N31signiﬁcantly different from the vehicle treatment in the M617 + KA
group (p b 0.001) (Figs. 6 and 8).
4. Discussion
In the present study,we investigated thepharmaceutical potential of
galanin receptor subtypes to block KA-induced neurodegeneration, as a
model for excitotoxicity. This study was motivated by the fact that
galanin has been shown to modulate excitability in the hippocampus
and administration of galanin has been shown to affect neurodegenera-
tion in several paradigms, including different epilepsymodels (Mazarati
et al., 2006). Several attempts have been made to characterize the con-
tribution of each galanin receptor subtype to different aspects of neuro-
protection; and both GAL1R and GAL2R have been shown to exert
neuroprotective effects (Elliott-Hunt et al., 2007; Mazarati and Lu,
2005; Schauwecker, 2010), while very few studies have addressed the
contribution of GAL3R in galanin-mediated neuroprotection.
To address the contribution of the individual receptor subtypes,
we designed and characterized a novel GAL1/2R agonist, namely the
M1154 peptide. The novel M1154 peptide was then compared with
two previously developed galanin receptor subtype selective ligands,
M617 which is GAL1R selective, and M1145 which is GAL2R selective.
To further improve the development of selective galanin receptor li-
gands,we here present a robust protocol for receptor signaling, utilizing
a label-free technique, to be able to test the receptor activation signature
of our receptor ligands on all three galanin receptor subtypes using
a single methodology. This is highly motivated since each galanin
receptor subtype has its own unique capacity to activate the differents Melanoma Cells expressing human GAL1R, HEK cells stably transfected with rat GAL2R or
EC50 GAL1R/EC50 GAL2R EC50 GAL3R/EC50 GAL2R
± 38 0.13 50
± 1090 0.46 120
± 502 79 170
,600 4.8 N1210
Fig. 4. Galanin receptor signaling studies. Potency of galanin receptor subtype selective ligands in the xCELLigence impedance based (RT-CES) system; Galanin (A-C), M617 (D-F), M1145
(G-I) andM1154 (J-L). Cells usedwhere BowesMelanomaCells expressinghumanGAL1R,HEK cells stably transfectedwith rat GAL2R or Flp-In T-REX293 cellswith inducible expression of
human GAL3R. The data is from three representative experiments performed in at least duplicates, presented as mean ± SEM. Calculated EC50 values are summarized in Table 4.
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selectivity for novel ligands. The xCELLigence system has similar or
improved sensitivity when compared to traditional endpoint assays
performed in the same laboratory (see Table 3). The relative low EC50
for galanin at GAL3R could reﬂect intrinsic receptor properties or
might be related to the utilized cell clone.We have earlier shown a sim-
ilar EC50-value for galanin, 530 nM (Table 3), in the commonly usedFig. 5. Galanin receptor signaling studies at HEK cells stably transfected with rat GAL2R.
Galanin dose response curve (closed circle) with an EC50 value of 8.2 nM was shifted to
the right by 1 nM (open square) M1154 given an EC50 value of 6.0 nM, 10 nM (closed
triangle) given an EC50 value of 5.8 nM, 100 nM (closed diamond) given an EC50 value
of 0.56 nM and 1000 nM (closed square) M1154 given an EC50 value of 0.045 nM.
Experiments were performed in duplicates and presented as mean ± SEM.GTPγ-assay (Runesson et al., 2009). It has been hypothesized in other
studies that transfection of cell lines with GAL3R yield very low and
variable receptor expression, which affect the possibility to detect the
signal efﬁcacy at this receptor (Ohtaki et al., 1999) (Berger et al., 2004;Fig. 6. Average seizure rating following i.c.v. administration of either saline, M617, M1145
orM1154 followed by i.c.v. injection of KA. Data presented asmeans±SEM.No signiﬁcant
differences in seizure rating between treatments were found using a two-way
contingency table analysis.
Fig. 7. Cell count from both dorsal (open bars) and ventral (closed bars) hippocampus
(region CA3) after i.c.v. administration of either saline, M617, M1145 or M1154 followed
by i.c.v. injection of KA. Data are presented as means ± SEM. # p b 0.05 ### p b 0.001 as
compared to ventral hippocampus in vehicle exposed animals, ** p b 0.01 as compared
to dorsal hippocampus in vehicle exposed animals; Kruskal–Wallis pairwise comparisons
test.
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GAL3R cell line, although, we have earlier shown that the GAL3R cell
clone used in this study has similar receptor expression as the GAL1R
and GAL2R cell lines (Runesson et al., 2009). Unfortunately, signaling
properties of the GAL3R and the pharmacological proﬁles of common
galaninergic ligands are still ill-deﬁned and more studies are needed
to characterize the properties of GAL3R (Lang et al., 2015).
Lundström and colleagues showed that M617 has agonistic proper-
ties at both GAL1R and GAL2R, evaluated through cAMP and IP assays,
with an EC50-value of 104 and 304 nM, respectively (Lundström et al.,
2005). A later publication ascribed the M617 peptide the ability to me-
diate activation of GAL3R, measured as the ability to inhibit forskolin
produced cAMP, at a similar concentration as for GAL1R and GAL2R,
with an EC50-value of 121 ± 48 nM (Sollenberg et al., 2010).
A recent publication reports a second wave of G-protein signaling
from internalized receptors in vesicles (Irannejad et al., 2013), which
might explain a persistent effect of added ligands to GPCRs that easily
can be detected using the real-time impedance based technology andFig. 8. Nissl stain images of dorsal hippocampus (CA3 region): (A) Nrelevant time sections can be determined for analysis. Furthermore,
very few studies address the contribution of GAL3R, mostly because
we still lack reliable pharmacological signatures at GAL3R for commonly
used galaninergic tools. Recently, multiple endoplasmic reticulum re-
tention motifs have been identiﬁed in the GAL3R, which can explain a
low cell surface expression in recombinant systems (Robinson et al.,
2013). Robinson and co-workers present a new cell line weremodiﬁca-
tions from GAL1R have been inserted to GAL3R in order to investigate
the intracellular trafﬁcking and function of GAL3R (Robinson et al.,
2013).
In the present study, we demonstrate the generation of a novel
galanin analog, M1154, with binding afﬁnities very similar to galanin
and the galanin fragment, galanin (1–16), towards GAL1R and GAL2R.
However, M1154 displays no ability to displace galanin at GAL3R in
binding studies up to 10 μM (Fig 1, Table 2). In addition, galanin and
galanin (1–16) were tested for comparison. The galanin fragment,
galanin (1–16), displays a 10 times lower Ki in this study compared to
an earlier publication (Smith et al., 1998), now more in concurrence
with the binding afﬁnity of the full-length peptide towards GAL3R, giv-
ing a similar binding proﬁle for the galanin and the galanin (1–16) pep-
tide on all three receptor subtypes (Table 2). We found that M1154, in
concurrence with galanin, to produce a clear stimulation through both
GAL1R and GAL2R in the xCELLigence system and in concordance with
the binding results, no activity was seen when tested at GAL3R (Fig 4).
Consistent with previous studies, the evaluation of the signal character-
istics of M617 andM1145 in the present study revealed these ligands to
also be GAL1R and GAL2R selective, respectively (Lundström et al., 2005;
Runesson et al., 2009; Sollenberg et al., 2010).
Administration of KA has been utilized as a model of both neurode-
generation and status epilepticus (Ben-Ari and Cossart, 2000; Wang
et al., 2005). We and others have shown that CA3 pyramidal cells are
most vulnerable to KA treatment (Ben-Ari and Cossart, 2000; Reiss
et al., 2009). Thus, KAprovides the opportunity to test theneural circuits
that protect CA3 neurons from hyperexcitability. Even so, there are
other obvious effects of i.c.v. KA-administration, such as induction of
seizure-typical behaviors. In the present study, i.c.v. administration
was utilized to insure a robust excitotoxic effect within the CA3 region,
which is mediated through a direct excitotoxic effect of KA. Therefore,
compounds that effectively reduce the KA-induced cell death in CA3
in this model most likely reﬂect neuroprotective effects not involved
in anticonvulsant activity.We previously reported that i.c.v. administra-
tion of a galanin receptor antagonist had no effect on seizure-typicalaive control, (B) Saline + KA, (C) M1154 + KA, (D) M617 + KA.
91K. Webling et al. / Neuropeptides 58 (2016) 83–92behaviors induced by i.c.v. administrated KA (Reiss et al., 2009). In the
present study none of the i.c.v. administrated galanin receptor agonists
at the chosen doses had an effect on the seizure-typical behaviors in-
duced by KA, depicted in Fig. 6. Doses of 20 μg has been shown to be at
the high end of the dose-range for i.c.v. administration of galanin peptide
analogs in previously reported behavioral studies (Lang et al., 2007; Saar
et al., 2011; Kuteeva et al., 2008). At 20 μg the GAL1R selective ligand
M617 was neuroprotective, in contrast to the GAL2R selective ligand
M1145. The novel GAL1/2R selective ligand M1154 were also neuropro-
tective and did not signiﬁcantly differ from M617, further supporting
GAL1R activation as neuroprotective. Testing higher doses would exceed
the range normally used for behavioral studies. Subsequently, with lower
doses it would be difﬁcult to reach statistical signiﬁcant differences to ve-
hicle due to the small effect size. However, it should be noted that the
commonly used technique involving a single dose of KA is not optimal
for measuring drug effects on acute behavioral seizures because of the
high variability observed between subjects (Reddy and Kuruba, 2013).
Thus, it can be speculated that the seizure-typical behaviors induced by
KA are galanin-independent and most likely due to overﬂow of KA and
hyperexcitability in themotor cortex (Sperk, 1994). Therefore,we cannot
exclude that these ligands have anticonvulsant properties.
I.c.v. administration of KA induces rigorous neuronal cell death in the
CA3 region of both ventral and dorsal hippocampus (Fig 7). Animals
treated with the GAL2R selective ligand, M1145, were equally affected
in the CA3 region by the i.c.v. KA-administration compared to vehicle
treated animals. In contrast, administration of the mixed GAL1/2R ago-
nistM1154 reduced cell loss signiﬁcantly. Furthermore, animals treated
with the GAL1R preferential ligand displayed further reductions in cell
death. These results indicate that the galanin-mediated neuroprotective
effect occurs through GAL1R and not GAL2R. This is in concordance with
earlier studies on inbredmicewhere a lower expression of GAL1R corre-
lated with a larger cell loss than wildtype littermates in the CA3 region
when exposed to KA (Kong et al., 2008; Schauwecker, 2010). Similar to
this study, these animals had no alteration in seizure-typical behaviors,
separating neuroprotective and anticonvulsant effects of the gala-
ninergic system (Schauwecker, 2010). The galanin ligands used in this
study were not chemically modiﬁed to increase stability or penetrate
the blood–brain barrier and are therefore expected to be degradated
within a fewminutes in serum (Bulaj et al., 2008) and i.c.v. administra-
tion was the administration route used in the animal studies. For possi-
ble pharmaceutical evaluation, chemically stabilized galanin analogs
would be preferable. Professor H. SteveWhite and colleagues have pre-
sented both GAL1R selective and GAL2R selective analogs that are sys-
temically active (Bulaj et al., 2008; Jequier Gygax et al., 2014;
Robertson et al., 2012; Robertson et al., 2010; White et al., 2009), as
well as peripherally active galanin ligands (Metcalf et al., 2015). Based
on the modiﬁcation presented by Bulaj et al. (Bulaj et al., 2008), novel
GAL2R selective ligands and one GAL2R speciﬁc ligand were generated
by Saar and colleagues (Saar et al., 2013).
5. Summary
A new protocol for evaluating novel GPCR ligands using real-time
impedance based technology showed similar or slightly lower EC50
values when compared to previously published galanin ligands EC50
values received from cAMP signaling in the same laboratory. M1154, a
novel GAL1/2R selective ligand was designed and its ability to signiﬁ-
cantly reduce the excitotoxicity of i.c.v. administered KAwas evaluated.
M1154was shown to be an agonist for both GAL1R and GAL2R. Our data
indicate, that M617 and M1154, but not M1145, signiﬁcantly reduced
neuronal cell death, in the KA-excitoxicity model. These ﬁndings sug-
gest that the neuroprotective effect of pharmacological stimulation of
galanin receptors in vivo after i.c.v. administration of KA in the CA3 re-
gion is mediated through GAL1R. This suggests that a GAL1R agonist
could potentially be used for treatment of exposure to excitotoxic
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